Cart
sales@molnova.com
GW1929
CAS No. 196808-24-9
GW1929( —— )
Catalog No. M22476 CAS No. 196808-24-9
GW1929 is a potent PPAR-γ agonist (pKi: 8.84 for human PPAR-γ; pEC50s of 8.56 and 8.27 for human and murine PPAR-γ).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 72 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 107 | In Stock |
|
| 25MG | 217 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGW1929
-
NoteResearch use only, not for human use.
-
Brief DescriptionGW1929 is a potent PPAR-γ agonist (pKi: 8.84 for human PPAR-γ; pEC50s of 8.56 and 8.27 for human and murine PPAR-γ).
-
DescriptionGW1929 is a potent PPAR-γ agonist (pKi: 8.84 for human PPAR-γ; pEC50s of 8.56 and 8.27 for human and murine PPAR-γ).GW1929 is a potent PPAR-γ activator, with pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, and pKis of 8.84, < 5.5, and < 6.5 for human PPAR-γ, PPAR-α, and PPAR-δ, respectively. GW1929 (10 μM) inhibits TBBPA-induced caspase-3 increase and TBBPA-stimulated LDH release in neocortical cell cultures [2].GW1929 (0.5, 1, 5 mg/kg, p.o.) highly decreases nonfasted plasma glucose levels in Zucker diabetic fatty (ZDF) rats after treatment for 14 days and possesses antilipolytic efficacy. In ZDF rats, GW1929 (1, 5 mg/kg, p.o.) increases glucose-stimulated insulin secretion of β-cell.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetPPAR
-
RecptorPPARγ
-
Research AreaCardiovascular system
-
IndicationType 2 diabetes mellitus
Chemical Information
-
CAS Number196808-24-9
-
Formula Weight495.57
-
Molecular FormulaC30H29N3O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:33 mg/mL (66.59 mM)
-
SMILESCN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Brown KK, et al. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes. 1999 Jul;48(7):1415-24.
molnova catalog
related products
-
Darglitazone
Darglitazone is a potent, selective agonist of PPAR-γ with antidiabetic actions. Darglitazone is effective in controlling blood glucose and lipid metabolism.
-
(±)4-HDHA
(±)4-HDHA (4-Hydroxy docosahexaenoic acid) is a PPARγ agonist with anti-inflammatory activity that directly inhibits endothelial cell proliferation and sprouting angiogenesis via PPARγ, which can be used in the study of diabetes.
-
WY-14643 (Pirinixic ...
WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with EC50 of 1.5 μM.
